Allergy Unit, Regional University Hospital of Malaga, IBIMA, UMA, Malaga, Spain.
Randall Division of Cell and Molecular Biophysics, Division of Asthma, Allergy and Lung Biology, King's College London, MRC-Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.
Clin Exp Allergy. 2015 May;45(5):872-881. doi: 10.1111/cea.12476.
Local allergic rhinitis (LAR) is characterized by the presence of a nasal Th2 inflammatory response with local production of specific IgE antibodies and a positive response to a nasal allergen provocation test (NAPT) without evidence of systemic atopy. The prevalence has been shown to be up to 25% in subjects affected with rhinitis with persistence, comorbidity and evolution similar to allergic rhinitis. LAR is a consistent entity that does not evolve to allergic rhinitis with systemic atopy over time although patients have significant impairment in quality of life and increase in the severity of nasal symptoms over time. Lower airways can be also involved. The diagnosis of LAR is based mostly on demonstration of positive response to NAPT and/or local synthesis of specific IgE. Allergens involved include seasonal or perennial such as house dusts mites, pollens, animal epithelia, moulds (alternaria) and others. Basophils from peripheral blood may be activated by the involved allergens suggesting the spill over of locally synthesized specific IgE to the circulation. LAR patients will benefit from the same treatment as allergic patients using antihistamines, inhaled corticosteroids and IgE antagonists. Studies on immunotherapy are ongoing and will determine its efficacy in LAR in terms of symptoms improvement and evolution of the natural course of the disease.
局部过敏性鼻炎(LAR)的特征是存在鼻 Th2 炎症反应,伴有局部特异性 IgE 抗体的产生,以及对鼻变应原激发试验(NAPT)的阳性反应,但没有全身过敏的证据。已经表明,持续性、合并症和演变与过敏性鼻炎相似的鼻炎患者中,LAR 的患病率高达 25%。尽管患者的生活质量显著受损,且随着时间的推移,鼻症状的严重程度增加,但 LAR 是一种持续存在的实体,不会随着时间的推移演变为伴有全身过敏的过敏性鼻炎。下呼吸道也可能受累。LAR 的诊断主要基于 NAPT 和/或局部合成特异性 IgE 的阳性反应的证明。涉及的过敏原包括季节性或常年性的,如尘螨、花粉、动物上皮、霉菌(交链孢霉)和其他过敏原。外周血中的嗜碱性粒细胞可能被涉及的过敏原激活,这表明局部合成的特异性 IgE 溢出到循环中。LAR 患者将受益于与过敏患者相同的治疗,使用抗组胺药、吸入皮质类固醇和 IgE 拮抗剂。免疫疗法的研究正在进行中,将确定其在 LAR 中改善症状和疾病自然病程方面的疗效。